BR112012024885A2 - composições bioadesivas de anestésicos locais - Google Patents

composições bioadesivas de anestésicos locais

Info

Publication number
BR112012024885A2
BR112012024885A2 BR112012024885A BR112012024885A BR112012024885A2 BR 112012024885 A2 BR112012024885 A2 BR 112012024885A2 BR 112012024885 A BR112012024885 A BR 112012024885A BR 112012024885 A BR112012024885 A BR 112012024885A BR 112012024885 A2 BR112012024885 A2 BR 112012024885A2
Authority
BR
Brazil
Prior art keywords
local anesthetics
bioadhesive
bioadhesive compositions
compositions
pharmaceutical composition
Prior art date
Application number
BR112012024885A
Other languages
English (en)
Portuguese (pt)
Inventor
Arne Brodin
Jonas Gustafsson
Mark Sundberg
Original Assignee
Pharmanest Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44278867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012024885(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmanest Ab filed Critical Pharmanest Ab
Publication of BR112012024885A2 publication Critical patent/BR112012024885A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/10—Medicinal preparations other than biologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/15—Laboratory, medical or dentistry appliances, e.g. catheters or sharps
    • A61L2103/20—Containers, e.g. vials or flasks

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112012024885A 2010-04-01 2011-03-31 composições bioadesivas de anestésicos locais BR112012024885A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1050322 2010-04-01
US32542510P 2010-04-19 2010-04-19
PCT/EP2011/055025 WO2011121082A1 (en) 2010-04-01 2011-03-31 Bioadhesive compositions of local anaesthetics

Publications (1)

Publication Number Publication Date
BR112012024885A2 true BR112012024885A2 (pt) 2016-06-21

Family

ID=44278867

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012024885A BR112012024885A2 (pt) 2010-04-01 2011-03-31 composições bioadesivas de anestésicos locais

Country Status (17)

Country Link
US (1) US20130079371A1 (cg-RX-API-DMAC7.html)
EP (1) EP2552409A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013523694A (cg-RX-API-DMAC7.html)
KR (1) KR20130080435A (cg-RX-API-DMAC7.html)
CN (1) CN102869344A (cg-RX-API-DMAC7.html)
AU (1) AU2011234415C1 (cg-RX-API-DMAC7.html)
BR (1) BR112012024885A2 (cg-RX-API-DMAC7.html)
CA (1) CA2794280A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012002705A1 (cg-RX-API-DMAC7.html)
EA (1) EA201290790A1 (cg-RX-API-DMAC7.html)
IL (1) IL222225A0 (cg-RX-API-DMAC7.html)
MX (1) MX2012011261A (cg-RX-API-DMAC7.html)
NZ (1) NZ602540A (cg-RX-API-DMAC7.html)
PH (1) PH12012501887A1 (cg-RX-API-DMAC7.html)
SG (1) SG184072A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011121082A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201206989B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308181B2 (en) 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
US9642912B2 (en) 2006-03-06 2017-05-09 Crescita Therapeutics Inc. Topical formulations for treating skin conditions
WO2010033726A2 (en) 2008-09-17 2010-03-25 The Brigham And Women's Hospital, Inc. Drug delivery composition comprising a self-assembled gelator
WO2012040623A2 (en) 2010-09-24 2012-03-29 The Brigham And Women's Hospital, Inc. Nanostructured gels capable of controlled release of encapsulated agents
KR101768843B1 (ko) * 2013-02-28 2017-08-17 미라 파마 코포레이션 주사가능 장기-작용 국소 마취제 반고체 제형 및 이의 조성물
US10220093B2 (en) 2013-02-28 2019-03-05 Mira Pharma Corporation Long-acting semi-solid lipid formulations
GB201317718D0 (en) 2013-10-07 2013-11-20 Buzzz Pharmaceuticals Ltd Novel formulation
WO2016152186A1 (ja) 2015-03-25 2016-09-29 テルモ株式会社 ゲル状局所麻酔剤およびそれを用いたゲル状局所麻酔製剤
AU2016352007B2 (en) 2015-11-12 2022-03-17 Terumo Kabushiki Kaisha Sustained-release topically administered agent
WO2018144991A1 (en) 2017-02-03 2018-08-09 The Brigham And Women's Hospital, Inc. Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
CA3061480A1 (en) * 2017-05-08 2018-11-15 Alivio Therapeutics, Inc. Formulation of nanostructured gels for increased agent loading and adhesion
US10561606B2 (en) 2017-12-06 2020-02-18 Mira Pharma Corporation Injectable long-acting local anesthetic semi-solid gel formulations
JP7046396B2 (ja) 2017-12-06 2022-04-04 湖州惠中濟世生物科技有限公司 注射可能な長時間作用性局所麻酔薬半固形製剤
US11426418B2 (en) 2017-12-06 2022-08-30 Mira Pharma Corporation Injectable long-acting semi-solid gel formulations
CN113825495A (zh) 2018-10-11 2021-12-21 阿利维奥治疗学股份有限公司 用于智能释放的不可注射水凝胶调配物
JP2024505227A (ja) * 2021-01-29 2024-02-05 インシツ バイオロジクス、インク. 疼痛の持続的治療のための組成物および方法
CN118697692B (zh) * 2024-06-27 2024-11-26 山东中医药大学附属医院 一种防苦麻醉胶浆剂、方法及应用
CN119587525B (zh) * 2024-11-07 2025-09-05 海南三帝制药有限公司 一种二甲卡因复合制剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
AU685262B2 (en) * 1994-03-30 1998-01-15 Gs Development Ab Use of fatty acid esters as bioadhesive substances
SE9601421D0 (sv) 1996-04-12 1996-04-12 Astra Ab New composition
JP2001503035A (ja) * 1996-10-14 2001-03-06 興和株式会社 外用局所麻酔剤
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US20060115522A1 (en) * 2003-02-17 2006-06-01 Cipla Ltd Pharmaceutical composition
US20050084508A1 (en) 2003-07-22 2005-04-21 Vancaillie Thierry G. Topical anesthesia formulation for bodily cavities
PL1845942T3 (pl) * 2005-01-14 2014-07-31 Camurus Ab Preparaty analogu GnRH
JP4931369B2 (ja) 2005-05-31 2012-05-16 ポーラ化成工業株式会社 リポソームおよびそれを含む処置用の組成物
CN101374554A (zh) * 2005-09-27 2009-02-25 埃弗拉特生物聚合物有限公司 胶凝疏水性可注射聚合物组合物
GB0524958D0 (en) * 2005-12-07 2006-01-18 Pharmakodex Ltd Transdermal administration of active agents
US20070280972A1 (en) * 2006-04-25 2007-12-06 Zars, Inc. Adhesive solid gel-forming formulations for dermal drug delivery
US20070269386A1 (en) * 2006-05-16 2007-11-22 Per Steen New product and use and manufacture thereof
JP5181320B2 (ja) * 2006-10-18 2013-04-10 ニチバン株式会社 皮膚刺激の少ない経皮吸収型製剤
US9918934B2 (en) 2006-12-12 2018-03-20 Edgar Joel Acosta-Zara Linker-based lecithin microemulsion delivery vehicles
US20090247494A1 (en) 2008-04-01 2009-10-01 Phillip Mark Kofsky Omega-3 essential fatty acid composition and method for treatment of anal and colon-rectal disorders

Also Published As

Publication number Publication date
AU2011234415C1 (en) 2014-07-10
CA2794280A1 (en) 2011-10-06
PH12012501887A1 (en) 2012-12-17
MX2012011261A (es) 2012-12-05
IL222225A0 (en) 2012-12-31
JP2013523694A (ja) 2013-06-17
US20130079371A1 (en) 2013-03-28
EA201290790A1 (ru) 2013-04-30
CL2012002705A1 (es) 2013-02-01
EP2552409A1 (en) 2013-02-06
ZA201206989B (en) 2014-04-30
SG184072A1 (en) 2012-10-30
NZ602540A (en) 2014-05-30
WO2011121082A1 (en) 2011-10-06
KR20130080435A (ko) 2013-07-12
AU2011234415B2 (en) 2014-04-10
AU2011234415A1 (en) 2012-10-18
CN102869344A (zh) 2013-01-09

Similar Documents

Publication Publication Date Title
MX2012011261A (es) Composiciones bioadhesivas de anestesicos locales.
BR112012024673A2 (pt) composição anestésica termogelificante
BR112014010290B8 (pt) Composição farmacêutica na forma de dispersão sólida de ativos específicos em polímeros específicos e uso da composição farmacêutica
DOP2013000239A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso.
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
DOP2011000285A (es) 2-acetamido-5-aril-1, 2, 4-triazolonas sustituidas y su uso
MX2014008457A (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
BR112013007362A2 (pt) composição farmacêutica
CO6690768A2 (es) Derivados de triazina-oxadiazoles, útiles como inhibidores de los canales de sodio navi.7
BR112014032809A8 (pt) urolitinas, usos de uma quantidade eficaz de uma urolitina ou um sal farmaceuticamente aceitável da mesma e composição compreendendo as mesmas
UY31228A1 (es) Ariloxazoles sustituidos y su uso
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
TN2011000471A1 (en) Pharmaceutical composition presenting anti-inflammatory properties
CL2011000214A1 (es) Composicion farmaceutica que comprende progesterona micronizada y aceite de cartamo tipo ii; y uso para el tratamiento de una condicion relacionada con la insuficiencia de secrecion de progesterona.
BR112015018838A2 (pt) estabilidade melhorada de novas composições líquidas
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
UY31922A (es) Compuestos
CR20110318A (es) Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos
GT201200284A (es) Composición farmacéutica
BR112015011430A2 (pt) composição para liberação imediata e prolongada
CL2012003681A1 (es) Compuestos derivados de piperidina; composicion farmaceutica; y su uso como inhibidores de acetil-coa carboxilasa para el tratamiento de trastornos metabolicos, tales como obesidad y diabetes.
BR112015032370A2 (pt) derivados de biarila, composição, e, método para preparar uma composição
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
CL2012003282A1 (es) Composicion farmaceutica topica que comprende, en base al peso total de la composicion a) 0,01 a 0,2% en peso de furoato de mometasona, b) 5 a 18% en peso de hexilenglicol, c) 20 a 40% en peso de agua y d) 25 a 70% en peso de una fase oleosa; y su uso para tratar o prevenir psoriasis, dermatitis atopica, entre otros.
DK2420223T3 (da) Vandige farmaceutiske sammensætninger med borat-polyol-komplekser

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.